论文部分内容阅读
目的：为满足丙型肝炎病毒（ＨＣＶ）ＥＩＡ检测的需要，构建含优势抗原表位的ＨＣＶ嵌合重组抗原。方法：利用基因工程重组技术，获得了不同的ＨＣＶ嵌合抗原ＮＣ１和ＮＣ２。含嵌合基因的表达质粒在大肠杆菌中表达了目的抗原，其中包括结构区核壳蛋白Ｃ２２和不同长度的非结构区蛋白ＮＳ３；表达产物经离子交换和盐析纯化。结果：用针对Ｃ２２或ＮＳ３抗原表位特异性血清及系列血清进行了检测，表明ＮＣ１和ＮＣ２均同时具有Ｃ２２和ＮＳ３抗原的免疫反应性。以嵌合抗原制备的抗ＨＣＶＥＩＡ试剂检测中国药品生物制品检定所的第三代Ｐａｎｅｌ血清时，其阳性、阴性通过率都符合要求。结论：构建的嵌合抗原有多个优势抗原表位，可用于ＨＣＶＥＩＡ检测
OBJECTIVE: To construct an HCV chimeric recombinant antigen with dominant epitopes in order to meet the needs of hepatitis E virus (HCV) EIA detection. Methods: The different HCV chimeric antigens NC1 and NC2 were obtained by genetic engineering recombinant technology. Expression plasmids containing the chimeric gene expressed the target antigen in E. coli, including the structural domain nucleocapsid protein C22 and the non-structural domain protein NS3 of different lengths; the expressed product was purified by ion exchange and salting out. Results: The detection of C22 or NS3 epitope-specific sera and serial sera showed that both NC1 and NC2 had both C22 and NS3 antigen immunoreactivity. The anti-HCVEIA reagent prepared by chimeric antigen detected the third-generation Panel Serum of China National Institute for the Control of Pharmaceutical and Biological Products, its positive and negative pass rates met the requirements. Conclusion: The constructed chimeric antigen has multiple dominant epitopes, which can be used for HCVEIA detection